Reports

Walmart reported $165.6 billion in revenue and $0.56 GAAP EPS for Q1 FY26, driven by strong eCommerce and advertising performance despite headwinds from leap day comparisons.

• Revenue reached $165.6 billion, up 2.5% YoY.
• Adjusted EPS came in at $0.61, above GAAP EPS of $0.56.

Applied Materials delivered a solid performance in Q2 2025 with $7.1B in revenue and record EPS, driven by growth in AI semiconductor demand and consistent shareholder returns.

• Achieved record GAAP EPS of $2.63 and non-GAAP EPS of $2.39.
• Revenue rose to $7.1B, reflecting continued strength in semiconductor demand.

Deere faced a challenging Q2 FY25 with declines in revenue and net income driven by decreased sales across Production & Precision Ag and Construction & Forestry segments. Despite this, Small Ag & Turf maintained stable profitability. The company broadened its full-year net income outlook due to market uncertainty.

• Net income for Q2 FY25 was $1.804 billion, down from $2.370 billion last year.
• EPS for the quarter was $6.64, compared to $8.53 in Q2 FY24.

NetEase delivered strong Q1 results with revenue reaching $4.00B and adjusted EPS of $2.44 per ADS, fueled by hit titles and sustained game engagement.

• Revenue reached $4.00B, reflecting growth in online game services.
• Adjusted EPS came in at $2.44 per ADS, supported by higher profitability.

Take-Two posted higher revenue and bookings in Q4 FY25, led by strong contributions from NBA 2K25, GTA Online, and Civilization VII. However, a massive goodwill impairment drove a multi-billion dollar net loss.

• Revenue rose 13% YoY to $1.5825 billion.
• Net loss reached $3.7262 billion due to $3.55 billion in goodwill impairment.

Hafnia Ltd delivered a net income of $63.2M in Q1 2025, down from the previous year, primarily due to 500 off-hire days for vessel maintenance. Despite reduced revenue and earnings, the company remained profitable and distributed $50.6M in dividends.

• Net income dropped to $63.2M due to drydocking and repair off-hire days.
• Revenue declined to $340.3M from $521.8M in Q1 2024.

KE Holdings delivered a solid Q1 2025, driven by robust performances in its home rental and new home segments. Total revenue increased significantly, and profitability improved across the board with net income almost doubling year-over-year.

• Revenue rose to $3.21 billion, reflecting strong performance in all segments, especially home rentals.
• Net income increased to $118 million, up from $58 million a year earlier.

CAVA Group delivered a solid performance in Q1 2025 with a 28.2% revenue increase, fueled by strong same-restaurant sales and continued expansion. The company achieved positive net income and adjusted EBITDA growth, highlighting operational efficiency and brand momentum.

• Revenue rose 28.2% year-over-year to $331,826,000.
• Net income increased to $25,707,000 with a 7.7% net income margin.

Birkenstock reported Q2 2025 revenue of €574 million and net income of €105 million, driven by robust demand in all regions and segments, with particularly strong performance in APAC and Americas. The company raised its full-year adjusted EBITDA guidance.

• Revenue grew 19% year-over-year to €574 million.
• Adjusted EBITDA increased to €200 million with margin expansion to 34.8%.

NICE delivered robust Q1 2025 results with 12% growth in cloud revenue and a 26% increase in GAAP EPS, supported by record operating cash flow and rising AI-driven adoption.

• Cloud revenue grew 12% YoY to $526.3M, making up 75% of total revenue
• GAAP EPS rose 26% YoY to $2.01, while non-GAAP EPS reached $2.87

Doximity reported strong financial results for the fourth quarter and fiscal year 2025, with significant year-over-year increases in revenue, net income, and cash flows. The company highlighted record engagement and the positive impact of its tools on medical professionals.

• Q4 total revenues reached $138.3 million, a 17% increase year-over-year.
• Q4 net income was $62.5 million, resulting in a 45.2% margin, up from 34.4% in the prior year.

Advanced Drainage Systems reported a decrease in financial results for the fourth quarter of fiscal year 2025, with net sales declining 5.8%, net income decreasing 19.6%, and diluted EPS falling 18.2%, largely influenced by unfavorable weather and the lingering impact of higher interest rates on construction markets.

• Net sales decreased by 5.8% to $615.8 million in the fourth quarter compared to the prior year.
• Net income decreased by 19.6% to $76.8 million, and diluted net income per share fell 18.2% to $0.99.

Globant achieved $611.1M in revenue and maintained healthy profitability amid macroeconomic challenges. The company emphasized its strategic focus on AI and a robust client pipeline for future growth.

• Revenue reached $611.1M, growing 7.0% YoY.
• Adjusted diluted EPS held strong at $1.50 despite macro pressures.

Dillard's reported a decrease in net income and total retail sales for the first quarter of fiscal year 2025 compared to the same period last year. Despite a challenging economic environment, the company maintained control over expenses and achieved a healthy gross margin. They also repurchased $98 million in stock and ended the quarter with $1.2 billion in cash and short-term investments.

• Net income decreased to $163.8 million from $180.0 million in the prior year's first quarter.
• Total retail sales decreased by 2% and comparable store sales decreased by 1%.

Webull's Q1 2025 performance was driven by 32% revenue growth and disciplined cost management, resulting in a 24.4% adjusted operating margin. User growth and customer assets also increased significantly year-over-year.

• Revenue reached $117.4M, up 32% YoY.
• Adjusted operating profit climbed to $28.7M with a 24.4% margin.

Zeekr Group delivered a strong Q1 2025 with improved margins and a notable reduction in net loss. Despite a sequential decline in revenue due to seasonality, the company made progress in profitability through integration synergies and disciplined cost control.

• Net loss narrowed to $105 million, a 60.2% YoY improvement.
• Vehicle margin rose to 16.5%, driven by cost efficiencies.

South Bow delivered $498 million in revenue and $88 million in net income during Q1 2025, with adjusted EPS of $0.47. Normalized EBITDA reached $266 million, and distributable cash flow totaled $151 million. The company maintained its leverage position while investing in strategic infrastructure and addressing operational incidents responsibly.

• Generated $498 million in revenue and $88 million in net income in Q1 2025.
• Normalized EBITDA was $266 million, slightly down from Q4 2024.

VEON delivered a robust Q1 2025 with 8.9% YoY revenue growth and a significant boost in EBITDA, driven by a 50.2% rise in direct digital revenue. The company's net income rose 50.9%, supported by strong performance in Pakistan and Ukraine.

• Total revenue reached $1.026 billion, up from $942 million in Q1 2024.
• EBITDA increased 13.7% YoY to $439 million.

Marex delivered a robust performance in Q1 2025 with a 28% increase in revenue and a 66% surge in profit before tax, supported by strong client activity and growth across all business segments.

• Adjusted profit before tax rose 42% to $96.3 million.
• Revenue grew 28% year-over-year to $467.3 million.

Bitdeer posted a net income of $409.5M in Q1 2025, primarily due to a large non-cash gain from derivative liabilities. Core operations struggled post-Bitcoin halving, with lower revenue, a negative gross profit, and an adjusted EBITDA loss.

• Total revenue dropped to $70.1M from $119.5M YoY.
• Net income surged to $409.5M due to $503.1M gain from fair value changes in derivative liabilities.

Adecoagro reported a significant decrease in Adjusted EBITDA for Q1 2025, down 60.1% year-over-year to $35.9 million. This decline was primarily due to a mark-to-market loss in biological assets in the Sugar, Ethanol & Energy business, lower crushing volume, and reduced Rice prices compared to record levels in Q1 2024. Despite these challenges, the Dairy business showed outperformance, and overall gross sales increased by 27.5% due to higher ethanol volumes sold.

• Adjusted EBITDA decreased by 60.1% year-over-year to $35.9 million in Q1 2025.
• Gross sales increased by 27.5% year-over-year, primarily driven by higher ethanol volumes and prices.

Falcon's Beyond reported consolidated revenues of $1.7 million and a net loss of $8.1 million for the first quarter of fiscal year 2025. The net loss improved significantly compared to the prior year due to changes in the fair value of earnout liabilities, although operating expenses increased.

• Consolidated revenue for Q1 2025 was $1.7 million.
• Net loss for Q1 2025 was $8.1 million, a significant improvement from the prior year.

Canadian Solar reported net revenues of $1.2 billion and a net loss of $34 million for Q1 2025. The company's solar module shipments increased year-over-year, and its e-STORAGE contracted backlog grew significantly. Despite ongoing market challenges, the company met or exceeded its guidance for shipments, revenue, and gross margin.

• Net revenues reached $1.2 billion, at the high end of guidance.
• Solar module shipments increased 9.4% year-over-year to 6.9 GW.

Quantum-Si achieved 84% YoY revenue growth in Q1 2025 with the successful launch of Platinum Pro units and ongoing investment in proteomics R&D. Operating expenses increased modestly as the company maintained focus on commercialization and product development.

• Revenue grew 84% year-over-year, reaching $842K.
• Net loss narrowed slightly to $19.2M from $19.5M last year.

Omeros Corporation posted a net loss of $33.5 million in Q1 2025 with no reported revenue. The company focused its efforts on advancing the FDA review of narsoplimab and reducing near-term debt obligations through note exchanges and equity conversions.

• Reported a net loss of $33.5 million, down from $37.2 million in Q1 2024.
• No revenue was recognized for the quarter as OMIDRIA royalties go directly to DRI.

Bit Digital generated $25.1M in revenue but reported a net loss of $44.5M for Q1 2025, driven by mark-to-market losses and a decline in mining revenue. Strong growth in cloud and colocation segments partially offset the impact.

• Total revenue reached $25.1M, down 17% year-over-year.
• Cloud services grew 84% YoY, becoming the largest revenue segment.

In Q1 2025, Gossamer Bio reported $9.9 million in collaboration revenue and a net loss of $36.6 million, while continuing to advance its registrational studies for seralutinib. The company closed new patient screening for its Phase 3 PROSERA Study and maintains a strong cash position to fund operations into the first half of 2027.

• Reported $9.9 million in collaboration revenue, including $6.6 million from cost reimbursements.
• Net loss decreased to $36.6 million from $41.9 million in Q1 2024.

In Q1 2025, Gaotu delivered robust financial performance with a 57.7% YoY increase in revenue, a return to profitability with RMB124.0 million in net income, and continued operational improvements. The company also announced a new share repurchase program worth $100 million.

• Revenue rose 57.7% YoY to RMB1.493 billion.
• Net income reached RMB124.0 million, reversing a loss from the prior year.

The company narrowed its net loss year-over-year and made notable regulatory strides for its TSHA-102 Rett syndrome program, receiving FDA alignment on the pivotal trial design.

• Net loss decreased to $21.5 million from $24.1 million a year ago.
• Revenue was $2.3 million for the quarter.

Xunlei reported a 10.5% year-over-year increase in total revenues for Q1 2025, reaching $88.8 million. This growth was primarily driven by increases in subscription revenue and overseas audio live-streaming business revenue. Despite revenue growth, the company reported a net loss of $0.9 million, compared to a net income in the same period last year, mainly due to increased operating loss.

• Total revenues increased 10.5% year-over-year to $88.8 million.
• Subscription revenues grew by 7.7% year-over-year to $35.7 million.

Silence Therapeutics reported a net loss of $28.5 million for Q1 2025, with revenues of $0.142 million. The company ended the quarter with $136.5 million in cash, cash equivalents, and short-term investments, and extended its cash guidance into 2028 through cost-saving initiatives.

• Advanced patient enrollment into the SANRECO Phase 2 study of divesiran for Polycythemia Vera (PV), remaining on-track to complete enrollment by year-end 2025.
• Additional Phase 1 results from the SANRECO study of divesiran in PV patients accepted for oral presentation at the European Hematology Association (EHA) 2025 Annual Congress.

Innventure posted a $254 million net loss for Q1 2025, largely driven by a $233 million goodwill impairment charge. Revenues remained flat year-over-year at $224,000. While Adjusted EBITDA was negative, the company highlighted promising business developments and reiterated confidence in second-half 2025 revenue growth.

• Reported $224,000 in revenue, flat from Q1 2024.
• Net loss attributable to stockholders was $143 million, primarily due to a $233 million goodwill impairment.

Seritage Growth Properties reported a net loss of $22.2 million for the first quarter of 2025, an increase from the $19 million net loss in the same period last year. Revenue decreased to $4.6 million from $5.8 million year-over-year. The company continues its Plan of Sale strategy to repay debt and monetize assets amidst challenging market conditions.

• Net loss for Q1 2025 was $22.2 million, compared to a net loss of $19 million in Q1 2024.
• Total revenue for Q1 2025 was $4.6 million, down from $5.8 million in Q1 2024.

Virgin Galactic posted a $84 million net loss for Q1 2025 on $500,000 in revenue, as it paused commercial flights to prioritize development of its Delta Class SpaceShips. The company maintained a strong liquidity position and reaffirmed its timeline for commercial operations starting in 2026.

• Revenue fell to $500,000 due to a pause in commercial spaceflights.
• Net loss improved to $84 million from $102 million a year ago.

Origin Materials posted $5.4M in revenue for Q1 2025, driven by its supply chain activation program. The company reported a net loss of $26.4M, impacted by a $16.6M non-cash impairment charge. Operating income declined significantly as commercial PET cap revenues were deferred. Cash reserves stood at $83M.

• Revenue was $5.4M, primarily from the supply chain activation program.
• Net loss widened to $26.4M due to increased operating expenses and a large impairment charge.

In Q1 2025, Wrap Technologies posted revenue of $765,000 and improved margins, bringing its net income into positive territory while continuing to reduce operating losses.

• Revenue for Q1 2025 reached $765,000.
• Gross margin improved significantly to 77.8%.

The company saw a year-over-year decline in collaboration revenue and a wider net loss. However, it progressed enrollment in its clinical trial for Emi-Le and maintains a solid cash position to support operations into mid-2026.

• Collaboration revenue dropped to $2.75 million from $9.25 million year-over-year.
• Net loss increased to $24.1 million compared to $19.3 million a year ago.

In Q4 2024, REE Automotive reported $12,000 in revenue and a GAAP net loss of $37.3 million. The company paused production and reduced expenses amid trade-related uncertainty, while emphasizing a shift toward licensing and partnership models.

• Q4 revenue was $12,000, down from $455,000 in Q4 2023.
• GAAP net loss widened to $37.3 million compared to $35.2 million in Q4 2023.

The company generated $11.3 million in PEMGARDA revenue while reducing R&D expenses and net loss compared to the same period last year. Invivyd remains focused on reaching near-term profitability and bolstering its antibody pipeline.

• PEMGARDA net product revenue was $11.3 million in Q1 2025, down from $13.8 million in Q4 2024.
• Net loss narrowed to $16.3 million, significantly improved from $43.5 million in Q1 2024.

Zomedica delivered record Q1 revenue led by growth in therapeutic devices and consumables, but posted a significant net loss driven by a large impairment charge.

• Revenue reached $6.5 million, a 4% increase year-over-year.
• Gross margin improved to 68%, up from 66% in Q1 2024.

Opus Genetics reported a net loss of $8.2 million for the first quarter of 2025, compared to a net loss of $7.1 million in the same period last year. Revenue increased to $4.4 million, primarily from a collaboration agreement. The company ended the quarter with $41.8 million in cash and cash equivalents.

• License and collaborations revenue increased to $4.4 million in Q1 2025, up from $1.7 million in Q1 2024.
• Net loss for Q1 2025 was $8.2 million, or $(0.24) per share, compared to a net loss of $7.1 million, or $(0.29) per share, in Q1 2024.

MiNK reported no revenue for the quarter but significantly reduced its cash burn and net loss year-over-year, while advancing its clinical programs in solid tumors and immune-mediated diseases. The company ended the quarter with $3.2 million in cash and is pursuing strategic partnerships and non-dilutive funding.

• Net loss for Q1 2025 was $2.8 million, improved from $3.8 million in Q1 2024.
• Cash used in operations was $1.3 million, a reduction from $2.5 million a year earlier.

Reviva Pharmaceuticals Holdings, Inc. reported a net loss of $6.1 million for the first quarter of 2025. The company's focus remains on advancing its late-stage brilaroxazine program.

• Net loss for Q1 2025 was $6.1 million.
• Research and development expenses were $4.7 million in Q1 2025.

XBP Europe Holdings reported a strong first quarter for 2025 with continued revenue growth, gross margin expansion, and improved Adjusted EBITDA, reflecting positive momentum and operational leverage.

• Revenue grew for the third consecutive quarter.
• Gross margin expanded on both a year-over-year and sequential basis.

ESS Tech generated $599K in revenue in Q1 2025, reflecting lower sales activity during its transition period. The company posted a net loss of $18M and an operating loss of $18.1M, with a sharp drop in cash reserves. Despite near-term financial challenges, commercial momentum for its Energy Base platform has gained traction.

• Revenue declined to $599K, down from $2.7M in Q1 2024, reflecting a slowdown in deliveries.
• Net loss was $18M as the company continues investing in its Energy Base strategy.

P3 Health Partners posted a net loss of $20.48 million in Q1 2025, with revenues down 4% year-over-year. Medical margin and operating income both declined, affected by prior-year claims. The company affirmed its full-year guidance, citing progress in its turnaround strategy.

• Revenue for Q1 2025 was $373,225,000, down from $388,488,000 in Q1 2024.
• Net loss attributable to controlling interest was $20,480,000.

Lazydays reported lower revenue due to dealership divestitures, but significantly narrowed net loss and improved operating margins. Adjusted EBITDA improved year-over-year, and the company enhanced its balance sheet by reducing debt through asset sales.

• Revenue was $165.8 million, down from $270.1 million in Q1 2024 due to dealership divestitures.
• Adjusted EBITDA improved to -$4.0 million from -$18.2 million year-over-year.

Precision BioSciences posted minimal revenue for Q1 2025 while advancing its lead in vivo gene editing programs. The company reported a net loss of $20.6 million and emphasized its strong cash position and progress in clinical trials for PBGENE-HBV and PBGENE-DMD.

• Q1 2025 revenue was under $0.1 million, down from $17.6 million in Q1 2024.
• Net loss for the quarter was $20.6 million, or $2.21 per share.

Cocrystal Pharma reported a reduced net loss and lower operating expenses in the first quarter of 2025 compared to the same period in the previous year. The company is advancing its antiviral product pipeline, particularly its norovirus candidate CDI-988, with plans for a human challenge study.

• Net loss for Q1 2025 was $2.3 million, a decrease from $4.0 million in Q1 2024.
• Research and development expenses decreased to $1.4 million in Q1 2025 from $3.0 million in Q1 2024.

AIM ImmunoTech's Q1 2025 results showed a significant reduction in net loss and operating expenses, despite a decline in revenue. The company faces potential delisting from the NYSE American due to non-compliance with stockholders' equity requirements.

• Net loss decreased to $3.705 million from $5.817 million year-over-year.
• Revenue declined to $16,000 from $40,000 in Q1 2024.

LM Funding America, Inc. reported total revenue of $2.4 million for Q1 2025, driven primarily by digital mining. The company experienced a net loss of $5.4 million and a Core EBITDA loss of $2.8 million, largely due to a non-cash Bitcoin write-down. Despite the loss, operational efficiency improved in digital mining, and the company generated revenue from curtailment and energy sales.

• Total revenue was $2.4 million, a sequential increase of 19.4% but a year-over-year decrease of 48.9%.
• Digital mining revenue accounted for $2.3 million, up 25.3% sequentially but down 50.1% year-over-year.

In Q1 2025, Workhorse generated $640,922 in revenue from commercial vehicle sales but posted a net loss of $20.6 million due to lower sales volume and high financing costs. The company continued to develop its electric truck lineup and received new customer orders while reducing operating expenses.

• Revenue declined to $640,922 from $1.34 million in Q1 2024, mainly due to lower W4 CC and W56 truck sales.
• Net loss was $20.6 million, or $4.68 per share, compared to $29.2 million loss last year.

Jaguar Health reported a 6% year-over-year revenue decline in Q1 2025, driven by reduced product sales. Operating and net losses widened compared to the prior year, and non-GAAP recurring EBITDA also declined. Despite the financial setbacks, Mytesi prescription volume grew slightly year-over-year.

• Revenue for Q1 2025 was $2,214,000, down 6% YoY and 37% QoQ.
• Net loss attributable to common stockholders was $10,465,000.

cbdMD reported $4.75 million in revenue in Q2 2025, up 8.6% YoY. Gross margin improved to 62%, and operating loss narrowed significantly. The company completed a capital restructuring and maintained strong direct-to-consumer sales while gaining momentum in new product lines like Herbal Oasis.

• Revenue rose to $4,749,426, up 8.6% from Q2 2024.
• Gross margin increased to 62% from 59% in Q2 2024.